ACE inhibitors for dogs are a class of blood pressure–lowering and kidney-protective drugs, most commonly enalapril, benazepril, and lisinopril, used mainly for congestive heart failure, systemic hypertension, and protein-losing kidney disease. They work by blocking the conversion of angiotensin I to angiotensin II, which lowers vascular resistance and reduces the kidney's protein leak. They are not a cure and are rarely used alone: in heart failure they are combined with diuretics (typically furosemide) and often pimobendan, and in kidney disease they are paired with dietary protein restriction and blood pressure control.
The renin-angiotensin mechanism, one level deeper
The body regulates blood pressure partly through the renin-angiotensin-aldosterone system, or RAAS. When kidney perfusion drops, juxtaglomerular cells release renin. Renin cleaves angiotensinogen into angiotensin I, and angiotensin-converting enzyme, found densely on pulmonary capillary endothelium, converts angiotensin I into angiotensin II. Angiotensin II is a potent vasoconstrictor and also triggers aldosterone release, which retains sodium and water.
ACE inhibitors bind the zinc site of that converting enzyme, so angiotensin I accumulates while angiotensin II falls. The immediate result is arterial and venous dilation. The secondary result, which matters more in chronic use, is reduced aldosterone-driven sodium retention and a lower glomerular capillary pressure.
The kidney effect is the counterintuitive part. ACE inhibitors dilate the efferent arteriole, the vessel leaving the glomerulus, more than the afferent vessel entering it. That lowers the pressure inside the glomerular filter. In a protein-losing kidney this is protective, because high intraglomerular pressure drives protein through the filtration barrier. In a dehydrated dog or one with severe pre-existing renal impairment, the same dilation can drop filtration enough to raise creatinine.
In plain terms: the drug protects the kidney long-term by turning down pressure at the filter, but that same pressure drop can look like kidney worsening on a blood test early in treatment.
Why the drug class is not interchangeable with others
ACE inhibitors block only one enzyme in the RAAS cascade. Angiotensin II can still be produced through alternative pathways, chiefly chymase, which is one reason the class has a ceiling effect and does not fully suppress the system. This matters when comparing drugs.
| Drug | Typical veterinary use | Elimination route | Practical note |
|---|---|---|---|
| Enalapril | Heart failure, hypertension, proteinuria | ~50% renal | Most studied in dogs; twice-daily dosing typical |
| Benazepril | Heart failure, proteinuria, kidney disease | ~50% hepatic, ~50% renal | Preferred in some renal patients because of hepatic clearance |
| Lisinopril | Hypertension, proteinuria | Primarily renal | Less veterinary data than enalapril; once-daily |
| Pimobendan | Heart failure (inotrope) | Hepatic | Different class; complements rather than replaces ACE inhibitors |
| Amlodipine | Systemic hypertension | Hepatic | Calcium channel blocker; often first-line for hypertension alone |
The quantified comparison that competes with the usual summaries: enalapril and benazepril differ mainly in elimination. Roughly half of a benazepril dose is cleared by the liver, versus a smaller hepatic fraction for enalapril, so benazepril is often chosen when renal function is already compromised. Per the 2019 ACVIM consensus on canine heart failure, ACE inhibitors remain standard adjunctive therapy, but the survival benefit is modest and additive to pimobendan and furosemide, not a standalone effect.
The timeline: what changes and when
ACE inhibitors act within hours but their measurable benefits accumulate over weeks. The table below reflects typical clinical expectations, not a guarantee for an individual dog.
| Time after starting | What is monitored | Expected finding |
|---|---|---|
| 1–2 hours | Blood pressure (if hypertensive) | 10–20% drop in systolic pressure possible |
| 3–7 days | Kidney panel (BUN, creatinine, SDMA) | Small creatinine rise acceptable if under ~30% |
| 1–2 weeks | Blood pressure recheck | Target systolic under 160 mmHg in most dogs |
| 2–4 weeks | Urine protein:creatinine ratio | Falling ratio signals kidney protection |
| 4–8 weeks | Repeat kidney panel and electrolytes | Potassium stability confirmed |
| Every 3–6 months | Full panel, blood pressure, weight | Long-term trend assessed |
The 3-to-7-day creatinine window is the most important early checkpoint. A rise of up to roughly 30% from baseline is generally tolerated as expected physiology; a larger jump warrants dose review or investigation for dehydration, per standard veterinary nephrology practice.
Dosing ranges and what determines them
Veterinary dosing is weight-based and titrated. These are typical starting ranges, not prescriptions.
- Enalapril: approximately 0.25–0.5 mg per kg every 12 hours for heart failure; lower starting point for hypertension.
- Benazepril: approximately 0.25–0.5 mg per kg every 24 hours, sometimes split to every 12 hours.
- Lisinopril: approximately 0.25–0.5 mg per kg every 24 hours.
The dose is adjusted for kidney function, blood pressure response, and tolerability. A dog with marginal renal function typically starts at the low end and is rechecked within a week. Cost is modest: a month of enalapril for a 30-pound dog commonly runs USD 15 to USD 40 depending on pharmacy and formulation, and generic human-tablet formulations are frequently used under veterinary direction.
Contraindications, red flags, and the potassium trap
ACE inhibitors reduce aldosterone, which normally excretes potassium. In a dog with kidney disease, or one also receiving a potassium-sparing diuretic or potassium supplement, this can push potassium into dangerous territory. Hyperkalemia above roughly 6.5 mEq/L is a medical concern and warrants urgent review; values approaching 7.0 mEq/L are an emergency.
Seek veterinary care promptly if any of the following appear after starting an ACE inhibitor:
- Vomiting, diarrhea, or refusal to eat lasting more than 24 hours
- Marked lethargy or weakness, which can signal low blood pressure or high potassium
- Muscle tremors or a slow, irregular heartbeat
- A creatinine jump greater than about 30% from baseline
- Swelling of the face or muzzle, which suggests a rare angioedema reaction
- Collapse or fainting
The potassium interaction is the non-obvious hazard most thin explainers omit: a kidney patient on benazepril plus a potassium supplement can become hyperkalemic without any change in dose.
Misconceptions worth correcting
A common misconception is that ACE inhibitors "cure" heart failure. They do not reverse structural heart disease; they reduce the workload on a failing heart and modestly extend comfortable time. Another is that a rising creatinine always means the drug is harming the kidney. The efferent-arteriole mechanism means a small, stable rise is expected physiology, and stopping the drug can remove its protective benefit.
A third correction: benazepril is not simply "enalapril for kidneys." The choice rests on elimination route, cost, and dosing frequency, not on a single organ target. Finally, ACE inhibitors are not appropriate for every hypertensive dog; amlodipine is often preferred for isolated hypertension, and the combination requires more frequent monitoring.
What to actually do
Start with a baseline: blood pressure, a full chemistry panel including creatinine and SDMA, a urine protein:creatinine ratio, and electrolytes to establish potassium. Recheck the kidney panel and potassium at 3 to 7 days, then blood pressure at 1 to 2 weeks, then the protein ratio at 2 to 4 weeks. Keep the dog hydrated and avoid sudden dietary sodium changes during titration. Record the dose, timing, and any vomiting or lethargy so the veterinarian can adjust precisely. Do not stop the drug abruptly without guidance, and do not add potassium supplements or potassium-sparing diuretics without discussing the interaction.
Limitations and what the evidence cannot promise
The survival benefit of ACE inhibitors in canine heart failure is real but modest, and most landmark veterinary data predates widespread pimobendan use, so the additive effect today is smaller than older trials implied. Evidence for benefit in early, asymptomatic heart disease is weaker, and routine use before clinical signs is debated. In kidney disease, protein reduction is a surrogate marker; it is associated with slower progression but not proven to guarantee it. Individual response varies with hydration, diet, concurrent drugs, and the dog's baseline renal reserve, so monitoring decisions should follow the individual trend rather than a single number.